GridAI Technologies Corp Dossier
Qualitative Analysis
Business overview
GridAI Technologies Corp. (NASDAQ: GRDX), formerly known as Entero Therapeutics, Inc. (and previously First Wave BioPharma, Inc.), is a diversified technology and life sciences company operating at the intersection of artificial intelligence and energy infrastructure. Following its 100% acquisition of Grid AI Corp. in late 2025, the company pivoted its primary focus toward a software-driven, grid-edge AI orchestration platform. This platform enables utilities, retail energy providers, and large power users (specifically hyperscale AI data center campuses) to dynamically manage electrical loads, distributed energy resources (DERs), and battery energy storage systems in real time. In addition to its core energy orchestration business, GridAI continues to maintain its legacy late clinical-stage biopharmaceutical pipeline, focusing on targeted, non-systemic therapies for gastrointestinal (GI) diseases, primarily centered on its Adrulipase program.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development of the core AI energy platform following the acquisition of AMPx, focusing on software-led recurring revenue models.
Expected impact: Establishment of a software-led recurring revenue model tied to long-term campus performance and orchestration fees.
Discontinuation of legacy biopharma programs including Latiglutenase, CypCel, Capeserod, and Niclosamide to focus resources on the core AI energy platform.
Expected impact: Allows the company to advance its sole remaining biopharma asset, Adrulipase, strictly as capital permits, while prioritizing energy orchestration.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Grid AI Corp. by the company (formerly a biopharmaceutical firm) to pivot its business model toward AI-driven energy orchestration for data centers and grid management.
Financial impact: Transformed the company from a pre-revenue biopharmaceutical firm to recognizing its first energy services revenue of $38K in Q1 2026.
Acquisition of a controlling interest by Grid AI Corp. to secure core grid-edge technologies, including Dynamic Load Shaping (DLS) and the Aggregation Management Platform (AMP).
Financial impact: Consolidated as the primary operating subsidiary, with an option exercised on September 30, 2025, to purchase an additional 24% interest for $7,000,000 in deferred consideration.
Strategic Partnerships
Identified as the primary partner to deploy GridAI's orchestration platform across a planned 5GW-plus portfolio of AI data center campuses over the next 5 to 10 years.
Terms: Structured to generate recurring operating revenue through software platform orchestration fees and energy performance optimization payments.